SCHEMBL732666

SCHEMBL732666

[c]1cc(Oc2ccccc2)nc(-c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
NPC1 O15118 2/20 0.50
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 3/20 0.44
ATM Q13315 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 2/20 0.39
LTA4H P09960 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9481848 0.88 LTA4H (0.50) MAPK1TDP1SMN1; SMN2RAB9ACYP1A2
SCHEMBL732707 0.79 MEN1 (0.53) MAPK1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL732423 0.77 MEN1 (0.62) TDP1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL18335708 0.77 RAB9A (0.58) MAPK1TDP1SMN1; SMN2RAB9ACYP1A2
SCHEMBL731107 0.75 MEN1 (0.37) MAPK1TDP1SMN1; SMN2RAB9ANPC1
SCHEMBL731199 0.75 NPC1 (0.54) MAPK1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL731043 0.74 SLC6A2 (0.48) MAPK1TDP1RAB9ANPC1MEN1
SCHEMBL14987893 0.70 MAPK1 (1.00) MAPK1TDP1SMN1; SMN2RAB9ACYP1A2
Pyridine SCHEMBL27666962 0.70 RAB9A (0.50) MAPK1TDP1SMN1; SMN2RAB9ACYP1A2
SCHEMBL16511926 0.70 F2 (0.48) MAPK1TDP1SMN1; SMN2RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 MAPK1 1666/4885TDP1 3806/4885SMN1; SMN2 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.